A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes

Trial Profile

A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2014

At a glance

  • Drugs Insulin aspart; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 05 Oct 2012 Multiple endpoints added and patient numbers updated to 117
    • 05 Oct 2012 The primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met for non-inferiority
    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top